All In Biotech

Drug Trial Radar · NCT00630032

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

Randomized, Open Label, Multicentric Phase III Evaluating the Benefit of a Sequential Regimen Associating FEC 100 and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients.

Last checked: Nov 19, 2026Latest source record: Feb 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 762 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

762

Actual

Start

Sep 2007

Primary completion

Jun 2017

Study completion Sep 3, 2020

Sponsor

Lead sponsor
UNICANCERAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 6, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them after surgery may kill any tumor cells remaining after surgery. It is not yet known whether docetaxel is more effective than ixabepilone when given after surgery and combination chemotherapy in treating breast cancer. PURPOSE: This randomized phase III trial is studying giving combination chemotherapy followed by docetaxel or ixabepilone to compare how well they work in treating patients who have undergone surgery for nonmetastatic breast cancer.

Conditions

  • Breast Cancer

Interventions

  • cyclophosphamideDrug

    500 mg/m² every 3 weeks

  • DocetaxelDrug

    100 mg/m² every 3 weeks

  • epirubicin hydrochlorideDrug

    100 mg/m² every 3 weeks

  • fluorouracilDrug

    500 mg/m² every 3 weeks

  • ixabepiloneDrug

    40 mg/m² every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Disease-free Survival (DFS)Time frame: At 5 years

Locations

86 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • CCOP - Colorado Cancer Research Program

    Denver, Colorado

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • CCOP - Northern Indiana CR Consortium

    South Bend, Indiana

  • CCOP - Cedar Rapids Oncology Project

    Cedar Rapids, Iowa

  • Siouxland Hematology-Oncology Associates, LLP

    Sioux City, Iowa

  • Cancer Center of Kansas, PA - Wichita

    Wichita, Kansas

  • Duluth Clinic Cancer Center - Duluth

    Duluth, Minnesota

  • Mayo Clinic Cancer Center

    Rochester, Minnesota

  • CCOP - Metro-Minnesota

    Saint Louis Park, Minnesota

  • Southeast Nebraska Hematology Oncology Consultants at Southeast Nebraska Cancer Center

    Lincoln, Nebraska

  • CCOP - Missouri Valley Cancer Consortium

    Omaha, Nebraska

  • Roger Maris Cancer Center at MeritCare Hospital

    Fargo, North Dakota

  • CCOP - Dayton

    Dayton, Ohio

  • CCOP - Geisinger Clinic and Medical Center

    Danville, Pennsylvania

  • Oncology Associates at Rapid City Regional Hospital

    Rapid City, South Dakota

  • Green Bay Oncology, Limited at St. Mary's Hospital

    Green Bay, Wisconsin

  • Institut Jules Bordet

    Brussels, Belgium

  • Centre de Sante des Fagnes

    Chimay, Belgium

  • Centre Hospitalier Hutois

    Huy, Belgium

  • Cazk Groeninghe - Campus Maria's Voorzienigheid

    Kortrijk, Belgium

  • CHR - Clinique Saint Joseph - Hopital de Warqueguies

    Mons, Belgium

  • Clinique Saint-Pierre

    Ottignies, Belgium

  • Clinique Universitaire De Mont-Godinne

    Yvoir, Belgium

  • Clinique Claude Bernard

    Albi, France

  • Centre Paul Papin

    Angers, France

  • Centre Hospitalier d'Annecy

    Annecy, France

  • Centre Hospitalier d'Auxerre

    Auxerre, France

  • Institut Sainte Catherine

    Avignon, France

  • Centre Hospitalier de Blois

    Blois, France

  • Institut Bergonie

    Bordeaux, France

  • Clinique Tivoli

    Bordeaux, France

  • Centre Hospitalier Docteur Duchenne

    Boulogne-sur-Mer, France

  • Centre Hospitalier de Fleyriat

    Bourg-en-Bresse, France

  • CHU Hopital A. Morvan

    Brest, France

  • Centre Regional Francois Baclesse

    Caen, France

  • Centre Hospitalier Regional de Chambery

    Chambéry, France

  • Centre Hospitalier de Chateaubriant

    Châteaubriant, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Clinique des Cedres

    Cornebarrieu, France

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.